SCHEMBL197885

SCHEMBL197885

COc1cc(-c2ccccn2)nc(-c2ccccn2)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 3/20 0.66
CCR1 P32246 4/20 0.58
CCR5 P51681 4/20 0.58
CCR8 P51685 4/20 0.58
LMNA P02545 4/20 0.57
SMN1; SMN2 Q16637 4/20 0.57
L3MBTL1 Q9Y468 4/20 0.57
KDM4E B2RXH2 2/20 0.57
TDP1 Q9NUW8 2/20 0.57
TP53 P04637 1/20 0.57
ALPL P05186 1/20 0.57
ALPI P09923 1/20 0.57
ALPG P10696 1/20 0.57
ALOX15 P16050 1/20 0.57
MAPK1 P28482 1/20 0.57
HTT P42858 1/20 0.57
METAP1 P53582 2/20 0.54
CYP1A2 P05177 1/20 0.54
POLB P06746 1/20 0.54
BLM P54132 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4735238 0.90 HSP90AA1 (0.59) HSP90AA1CCR1CCR5CCR8LMNA
SCHEMBL6130670 0.90 HSP90AA1 (0.56) HSP90AA1CCR1CCR5CCR8LMNA
SCHEMBL1366769 0.88 HSP90AA1 (0.58) HSP90AA1CCR1CCR5CCR8LMNA
SCHEMBL14615313 0.88 HSP90AA1 (0.58) HSP90AA1CCR1CCR5CCR8LMNA
SCHEMBL9341045 0.87 HSP90AA1 (0.69) HSP90AA1CCR1CCR5CCR8LMNA
SCHEMBL2711382 0.85 CCR1 (0.77) HSP90AA1CCR1CCR5CCR8LMNA
Dipyridyl SCHEMBL9014122 0.85 CCR1 (0.77) HSP90AA1CCR1CCR5CCR8LMNA
Dipyridyl SCHEMBL9014402 0.85 CCR1 (0.77) HSP90AA1CCR1CCR5CCR8LMNA
SCHEMBL7454751 0.84 NPC1 (0.57) HSP90AA1CCR1CCR5CCR8LMNA
SCHEMBL31260432 0.84 NPC1 (0.57) HSP90AA1CCR1CCR5CCR8LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9891185-B2 Small volume in vitro analyte sensor ABBOTT DIABETES CARE INC. (US) 2018-02-13 US disclosed
US-9662057-B2 Integrated sample acquisition and analyte measurement method ABBOTT DIABETES CARE INC. (US) 2017-05-30 US disclosed
US-20160334356-A1 Small Volume In Vitro Analyte Sensor THERASENSE, INC. 2016-11-17 US disclosed
US-20160235350-A1 Integrated Sample Acquisition and Analyte Measurement Device THERASENSE, INC. 2016-08-18 US disclosed
US-9341591-B2 Small volume in vitro analyte sensor ABBOTT DIABETES CARE INC. (US) 2016-05-17 US disclosed
US-9316609-B2 Small volume in vitro analyte sensor ABBOTT DIABETES CARE INC. (US) 2016-04-19 US disclosed
US-9291592-B2 Small volume in vitro analyte sensor ABBOTT DIABETES CARE INC. (US) 2016-03-22 US disclosed
US-9271669-B2 Method for integrated sample acquisition and analyte measurement device ABBOTT DIABETES CARE INC. (US) 2016-03-01 US disclosed
US-9234863-B2 Small volume in vitro analyte sensor ABBOTT DIABETES CARE INC. (US) 2016-01-12 US disclosed
US-9188590-B2 Labeled transition metal complexes LEICA BIOSYSTEMS NEWCASTLE LTD. (GB) 2015-11-17 US disclosed
US-20030199744-A1 Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator THERASENSE, INC. (US) 2003-10-23 US disclosed
US-6618934-B1 Method of manufacturing small volume in vitro analyte sensor THERASENSE, INC. 2003-09-16 US disclosed
US-6592745-B1 Analytical sensors for the detection of bioanalytes in a small volume sample; to monitor glucose in diabetic patients and lactate during critical care THERASENSE, INC. 2003-07-15 US disclosed
US-6591125-B1 Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator THERASENSE, INC. 2003-07-08 US disclosed
US-6461496-B1 BLOOD GLUCOSE THERASENSE, INC. 2002-10-08 US disclosed
EP-0885233-B1 TERPYRIDINE-PLATINUM(II) COMPLEXES ISIS INNOVATION (GB) 2002-06-19 EP disclosed
US-20020013306-A1 TERPYRIDINE-PLATINUM(II) COMPLEXES ISIS INNOVATION LIMITED (GB) 2002-01-31 US disclosed
US-6338790-B1 DETECTION OF BIOANALYTES IN A SMALL VOLUME SAMPLE; CONCENTRATION OF A BIOMOLECULE, SUCH AS GLUCOSE OR LACTATE, USING TECHNIQUES SUCH AS COULOMETRY, AMPEROMETRY, AND POTENTIOMETRY. AN ENZYME CAPABLE OF CATALYZING THE THERASENSE, INC. 2002-01-15 US disclosed
EP-1164138-A1 Terpyridine-platinum (II) complexes ISIS INNOVATION LIMITED (GB) 2001-12-19 EP disclosed
US-6299757-B1 ANALYTICAL SENSORS FOR THE DETECTION OF BIOANALYTES; ESPECIALLY MONITORING GLUCOSE LEVELS IN DIABETIC PATIENTS THERASENSE, INC. 2001-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013306-A1 TERPYRIDINE-PLATINUM(II) COMPLEXES TOP2A, TOP1, TOP2B HSP90AA1 1133/4885CCR1 1921/4885CCR5 884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.